|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01513 LIVZON PHARMA
Nominal 
25.950 -0.100 (-0.384%) | 2022/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | 2018/12 RMB(K¥) | |
| Turnover | 12,629,579 | 4.689% | 12,063,863 | 10,520,410 | 9,384,696 | 8,860,656 |
| Cost of Sales | -- | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- | -- |
| 2022/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | 2018/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (197,582) | 126.217% | (87,342) | (64,750) | (56,756) | (39,478) | |
| Profit / (Loss) on Disposal | 861 | -87.765% | 7,035 | (1,072) | 460 | (549) | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 61,202 | 56.671% | 39,064 | 1,907 | (10,686) | (6,187) | |
| Profit / (Loss) before Taxation | 2,330,551 | 3.779% | 2,245,689 | 2,489,436 | 1,727,542 | 1,416,674 | |
| Taxation | (374,973) | 27.721% | (293,588) | (358,109) | (265,965) | (234,960) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (46,170) | -73.829% | (176,418) | (416,416) | (158,702) | (99,540) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 1,909,408 | 7.531% | 1,775,683 | 1,714,910 | 1,302,875 | 1,082,175 | |
| 2022/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | 2018/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (268,761) | 283.721% | (70,041) | (103,639) | (220,799) | (251,952) |
| Depreciation & Amortisation | 685,630 | 45.464% | 471,339 | 423,391 | 415,495 | 381,566 |
| Directors' Emoluments | 18,702 | -5.524% | 19,795 | 17,177 | 15,859 | 8,934 |
| 2022/12 - Final | %Chg (Compare to Final) | 2021/12 | 2020/12 | 2019/12 | 2018/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2022/12 - Final | %Chg (Compare to Final) | 2021/12 | 2020/12 | 2019/12 | 2018/12 | |
| EPS (cts) | 204.000 | 7.368% | 190.000 | 183.000 | 139.000 | 116.000 |
| DPS (cts) | 160.000 | -- | 130.000 | 125.000 | 115.000 | 92.308 |
| Dividend Payout Ratio (%) | 78.431% | -- | 68.421% | 68.306% | 82.734% | 79.576% |
| Cash flow per share ($) | 2.965 | -- | 2.034 | 2.308 | 1.890 | 1.356 |
| NBV per share ($) | 14.832 | -- | 13.865 | 12.814 | 11.946 | 11.395 |
| Remarks: | Real time quote last updated: 10/02/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,170,971 |
| %Change | 3.208% |
| EPS / (LPS) | RMB 1.270 |
| NBV Per Share (¥) | RMB 15.027 |